Table 2.

Of cell growth inhibition of MCF-7 and MDA-MB-231 breast cancer cells after 72 h of co-administration of ZER or ZER-HPβCD with TP5-iRGD peptide.

Co-administration Ratio	MCF-7 (% of Inhibition)	MDA-MB-231 (% of Inhibition)
Compound (IC50): TP5-iRGD	ZER	ZER-HPβCD	ZER	ZER-HPβCD
1:10 X	91.4 ± 3.0	90.4 ± 4.2	58.1 ± 8.8	41.5 ± 20.4
1:20 X	67.6 ± 3.9	85.8 ± 7.0	44.0 ± 8.6	72.8 ± 2.3
1:30 X	72.1 ± 8.6	68.5 ± 13.2	48.3 ± 5.4	79.1 ± 1.8

Data are presented as mean ± SD; ZER: zerumbone, ZER-HPβCD: zerumbone encapsulated in hydroxypropyl-β-cyclodextrin.